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Abstract
Esophageal cancer is associated with malnutrition in the vast majority of patients. This 
phenomenon is partly attributed to the disease process itself, the location of the tumor 
and other factors, such as dysphagia which is often accentuated due to chemotherapy/
radiotherapy treatment or surgical intervention. The poor nutritional status of these 
patients is often related to the presence of cancer cachexia, altered metabolism, and tissue 
wasting. Malnutrition in this patient population affects quality of life, worsens patient’s 
tolerance to chemotherapy and accounts for lower survival. Nutritional management 
of these patients includes both proper nutritional assessment and support and might 
prevent, to a certain extent, the manifestation of malnutrition‐related consequences. The 
purpose of this article is to review the current literature in order to focus on the etiology 
and diagnosis of malnutrition in esophageal cancer patients, emphasizing also on the 
optimal nutritional support during multimodality treatment.
Keywords: nutritional assessment, nutritional support, perioperative nutritional care, 
esophageal cancer
1. Introduction
Esophageal cancer is one of the most fatal cancers worldwide as it was ranked ninth for cancer 
incidence and sixth for cancer death in 2013. In 2013, there were 442,000 new cases of esopha‐
geal cancer and 440,000 deaths [1]. There are two main histologic subtypes of esophageal 
cancer: squamous cell carcinoma and adenocarcinoma, each one of them is related to several 
risk factors. Among them, modifiable lifestyle factors, such as alcohol consumption, tobacco 
use, and nutrition should be considered as key points in order to prevent esophageal cancer. 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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Excess alcohol consumption and consumption of hot food and beverages increase the risk of 
esophageal squamous cell carcinoma, whereas many components of Western type diet, such 
as red and processed meat increase the risk of esophageal adenocarcinoma [2–4]. Moreover, 
obesity, especially central type, and gastroesophageal reflux disease are risk factors toward 
developing esophageal adenocarcinoma [5, 6]. On the other hand, healthy dietary habits 
could be a shield against some types of esophageal cancer [7], while nutritional support could 
be beneficial for the management of these patients after cancer diagnosis.
Esophageal cancer is commonly associated with malnutrition and impaired nutritional intake. 
Nutritional management of these patients may differ according to the type of therapy and 
stage of disease, in order to alleviate symptoms, ameliorate nutritional status, and improve 
quality of life. Furthermore, cancer cachexia affects a great percentage of esophageal can‐
cer patients emerging as a significant factor the multidisciplinary team should deal with [8]. 
Regarding the perioperative care, the proper type of feeding (i.e. enteral/parenteral nutrition 
(EN/PN), immunonutrition, oral supplements, etc.) as well as the right time of feeding is a 
matter of controversy due to lack of consistent evidence for patients undergoing esophagec‐
tomy [9]. Special nutritional needs in the long run are also of great significance for patients 
with both resectable and unresectble disease, bearing in mind that the majority of these 
patients strive to meet their caloric and protein needs. Considering the treatment approach, 
nutritional screening and assessment leads to early detection of malnourished patients in 
need of nutritional support. Taking into account patient’s specific needs helps to choose the 
most suitable routes of delivering nutritional support (nutritional counseling and artificial 
nutrition). Personalized nutritional support could modify poor nutritional status resulting in 
reduced postoperative complications and improved survival. Moreover, the implementation 
of nutritional protocols could reduce toxicity of treatment regimens and in conjunction with 
nutritional monitoring could have impact on patients’ daily living [10]. Therefore, nutritional 
therapy should be an essential part of a multidisciplinary approach in the clinical setting, in 
order to improve short‐ and long‐term outcomes.
The aim of the current review is to focus on the etiology of malnutrition, review the various 
methods of nutritional assessment, and analyze the aspects of nutritional management of 
esophageal cancer patients as a fundamental part of multimodality therapy.
2. Nutritional status
2.1. Malnutrition rates and weight loss
Esophageal cancer patients often suffer from malnutrition, the manifestation of which is 
strongly linked to the stage of the disease and therapeutic regimens. Excessive weight loss is 
partly attributed to the disease process itself and is often deteriorated due to chemotherapy/
radiotherapy treatment [11]. Malnutrition occurs in 60–85% of esophageal cancer patients, 
which is one of the highest reported rates when compared to other malignancies, such as 
lung, head and neck, stomach, and pancreatic cancers [12]. According to recent publications, 
32% of patients who underwent esophagectomy experienced more than 10% weight loss 
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preoperatively [13], while 90% of patients had a 5% weight loss at 3 months postoperatively 
[14]. It is noteworthy that in many patients weight loss persists for at least 3 years after surgi‐
cal intervention [15]. Another study revealed that 43.8% of patients with esophageal cancer 
were underweight based on BMI values, 29.7% of patients were undernourished as indicated 
from anthropometric measurements and 69% had weight loss within 2 weeks before hos‐
pital admission [16]. Chemotherapy and radiotherapy affect nutritional status by promot‐
ing weight loss and muscle wasting. More specifically, malnutrition developed in 83.8% of 
patients after the end of radiotherapy [17] and the number of patients requiring nutritional 
intervention increased from 56 to 75% during induction chemotherapy [10]. These facts high‐
light the need of nutritional assessment at several time points in order to identify patients 
who are candidates for nutritional support.
2.2. Methods of nutritional assessment and impact on clinical outcome
There are various methods of nutritional assessment in the clinical setting providing cli‐
nicians with tools for the evaluation of the nutritional status and the estimation of nutri‐
tional needs of esophageal cancer patients. One commonly used criterion of malnutrition 
is the percentage of weight loss in a certain period of time. Α weight loss of more than 5% 
in the previous month or more than 10% in the last 3–6 months is considered significant 
malnutrition [18]. One retrospective study concluded that weight loss <10% and BMI>18 
kg/m2 were significantly correlated with a better response to chemoradiotherapy, while 
BMI>18 kg/m2 was predictive of survival at both univariate and multivariate analysis [19]. 
Other anthropometric measurements, such as mid‐arm circumference and mid upper‐arm 
muscle area can give information about the nutritional status and body composition of 
these patients.
Biochemical markers, such as plasma proteins are often used as nutritional markers. For 
instance, albumin is commonly used for the assessment of protein status, but given its long 
half‐life (14–20 days), it has a slow response to dietary interventions and cannot detect subtle 
changes in nutritional status. Furthermore, albumin reflects an acute phase response and is 
not always a reliable marker of malnutrition [20]. However, albumin is an independent risk 
factor for complications after esophagectomy, since patients with hypoalbuminemia have 
twice the risk of postoperative infection and increased incidence of acute respiratory distress 
syndrome [21]. A recent review examined the association of serum albumin with postop‐
erative complications in patients undergoing esophagectomy, suggesting that low serum 
albumin does increase the risk of postoperative complications, but there is still conflicting 
evidence regarding the prognostic value of this biomarker [22].
Other methods of nutritional assessment include questionnaires that incorporate many 
factors that impede adequate nutritional intake, as well as laboratory parameters, and 
unintentional weight loss. For example, Subjective Global Assessment (SGA), a question‐
naire based on four parameters of patient’s history (percentage of weight loss, changes in 
habitual diet, presence of significant gastrointestinal symptoms, and changes in patient’s 
functional capacity) and three elements of their physical examination (loss of subcutane‐
ous fat, muscle wasting, and presence of edema or ascites) is one the most commonly 
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used tool for nutritional screening in malnourished hospital patients with cancer. SGA 
is strongly correlated with performance status in esophageal cancer patients [16] as well 
as with The Glasgow prognostic score and with complications during cancer treatment 
[23]. Other tools that have been studied in cancer patients is the Prognostic Nutritional 
Index (PNI), the Nutritional Risk Screening 2002 (NRS 2002), the Controlling Nutritional 
Status (CONUT) and the Nutritional Risk Index (NRI). Esophagectomized patients with 
a high Prognostic Nutritional Index—a tool which includes serum albumin and absolute 
peripheral lymphocyte count—had a higher prevalence of postoperative complications 
[24]. These results are in accordance with later studies, indicating that nutritional status 
preoperatively, expressed as PNI, was significantly related with the occurrence of severe 
complications and was a predictive factor for long‐term survival [25, 26]. Nevertheless, 
Han‐Geurts et al. showed that PNI was not associated with postoperative infectious com‐
plications in patients who underwent esophageal resection for malignancy [27]. NRS‐2002 
is recommended by the European Society for Clinical Nutrition and Metabolism as a stan‐
dard tool for the assessment of surgical patients [28], but it is not tailored to esophageal 
cancer patients, thus limiting its prognostic value in this population. The CONUT score, 
which is calculated by serum albumin concentration, total peripheral lymphocyte count, 
and total cholesterol concentration, was developed as a screening tool for early detec‐
tion of patients at risk of malnutrition [29]. Patients classified preoperatively as moderate 
or severe malnourished had a higher incidence of pulmonary and other severe morbidi‐
ties, surgical site infections, and reoperation. Consequently, the duration of hospital stay 
in patients with moderate or severe malnutrition was significantly longer compared to 
well‐nourished or slightly malnourished patients [30]. Similarly, Hirahara et al. [31] and 
Toyokawa et al. [32] demonstrated that CONUT was significantly associated with cancer 
death and poorer disease‐free survival in patients with resectable esophageal squamous 
cell carcinoma. NRI is another tool used for the assessment of malnutrition based on serum 
albumin concentration and weight loss. Ιncreased nutritional risk, derived from NRI, is 
associated with reduced survival in esophageal cancer patients treated with definitive 
chemoradiotherapy [10, 33], but is not associated with postoperative infectious complica‐
tions in patients treated with esophagectomy [27]. The Geriatric Nutritional Risk Index 
(GNRI) is a new index recently introduced for the assessment of nutritional status of 
elderly patients. Patients diagnosed with poor nutritional status according to GNRI had 
significantly higher rate of respiratory complications after esophagectomy and gastric tube 
reconstruction [34]. In conclusion, there are several nutrition assessment tools for esopha‐
geal cancer patients, but since many of the studies mentioned above are of retrospective 
nature, the gold standard for the evaluation of nutritional status in this cancer subpopula‐
tion is yet to be determined (Table 1).
Percentage of unintentional  
weight loss
Biochemical markers  
(albumin, prealbumin, 
 total peripheral  
lymphocyte count)
Questionnaires and indices:  
SGA, NRS2002, CONUT,  
NRI, PNI, Glasgow  
Prognostic Score
Table 1. Nutritional assessment of esophageal cancer patients.
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2.3. Sarcopenia and cancer cachexia
Patients with esophageal cancer often witness loss of muscle mass and/or muscle strength, a 
condition described as sarcopenia. Although there are many different definitions of the term 
sarcopenia, all of them place emphasis on the impaired physical function following decreased 
muscle mass [35–37]. Sarcopenia is a component of cancer cachexia, especially in advanced 
stage cancer patients. Cancer cachexia is a complex syndrome which combines anorexia, early 
satiety, weakness, anemia, inflammation, weight loss, and loss of muscle mass with or with‐
out loss of fat mass [38]. A recent study pointed out that the prevalence of cancer cachexia in 
advanced esophageal cancer patients was 52.9% [39]. There is lack of consensus on the defini‐
tion, diagnostic criteria, and classification of cancer cachexia, but the most commonly used 
definition includes one of the following: Weight loss >5% over past 6 months (in absence of 
simple starvation); or BMI <20 and any degree of weight loss >2%; or appendicular skeletal 
muscle index consistent with sarcopenia (males <7.26 kg/m2; females <5.45 kg/m2),and any 
degree of weight loss >2% [40]. Furthermore, assessment of sarcopenia plays an emerging role 
in cancer patients owing to the fact that CT scanning is a gold standard imaging method of 
body composition analysis at the tissue‐organ level [41]. CT scans can identify reduced muscle 
mass and predict negative cancer outcomes in people with abdominal malignancies, where 
traditional methods of assessment are less effective [42]. Handgrip strength is another method 
used to measure muscle strength, which is directly related to the physiologic status of the 
individual and reflects patient’s nutritional status. It could be easily used in patient’s nutri‐
tional assessment due to the fact that it is an inexpensive and not time‐consuming method.
Sarcopenia and cachexia are prognostic factors for surgical complications, decreased survival, 
and poor response to chemotherapy. More specifically, patients with weak handgrip strength 
had higher risk of complications and mortality after elective esophagectomy [43]. Decreased 
muscle mass, assessed by preoperative computed tomography scans, seems to be an indepen‐
dent predictor of both overall survival (Figure 1) [44] and disease‐free survival, as significant 
as tumor stage, in patients following esophagectomy [45, 46]. In addition, sarcopenic patients 
who underwent esophagectomy had significantly higher rate of respiratory complications 
compared to nonsarcopenic subjects, but there was no difference in the incidence of overall 
complications between the two groups [47–49]. Sarcopenia has also impact on chemotherapy 
outcome since decreased muscle mass is associated with dose‐limiting toxicity and patho‐
logical chemotherapy response in patients receiving neoadjuvant chemotherapy [50–52]. 
Therefore, it is imperative to estimate patients’ muscle mass not only preoperatively but also 
before the οnset of chemotherapy, bearing in mind that sarcopenia is frequently masqued by 
obesity making it more difficult to define patients’ needs for intervention.
2.4. Mechanisms of malnutrition
Malnutrition, as mentioned above, affects a great percentage of esophageal cancer patients. 
Most patients are not able to achieve a positive energy balance and in many cases, initial body 
weight cannot even be maintained. This is ascribed mainly to impaired metabolism and side 
effects caused by esophagectomy or chemotherapy/radiation treatment. Dysphagia is a very 
common mechanical cause of malnutrition and is accompanied by dietary changes in order to 
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avoid foods that worsen symptoms leading to inadequate intake of calories. The surgical pro‐
cedure often causes deficiencies in macronutrients and micronutrients, with the most prevail‐
ing side effects being postprandial dumping syndrome, dysphagia, anorexia, reflux, and early 
satiety [53–55]. Furthermore, chemotherapy affects rapidly proliferating cells preferentially 
and, consequently, affects the cells of the gastrointestinal tract. Chemotherapy‐related causes 
of reduced food intake include nausea, vomiting, diarrhea, mucositis, and decreased appetite. 
Radiotherapy also contributes to malnutrition, and combined with chemotherapy exacerbates 
patients’ nutritional status. Common side effects of radiotherapy include mucositis, esopha‐
gitis, odynophagia, mouth and throat soreness, and hypogeusia [56]. Tumor‐related causes of 
malnutrition are also of great significance, but the mechanisms involved are still under inves‐
tigation. Cancer‐induced anorexia may result from circulating factors produced by the tumor 
or by the host in response to the tumor. For instance, cytokines, such as interleukins (IL) and 
tumor necrosis factor‐alpha (TNF‐α) cause anorexia [57], whereas other tumor‐secreted fac‐
tors promote central‐ and peripheral‐mediated cancer cachexia. Tumor growth results in the 
secretion of pro‐inflammatory factors that promote cachexia by signaling anorexia, muscle 
wasting, and white adipose tissue atrophy. Tumors also secrete both the proteolysis‐inducing 
factor and activin, which promote skeletal muscle degradation and sarcopenia [58, 59].
Even though the mechanisms behind muscle wasting have been widely studied, less is known 
about the factors implicated in adipose tissue loss in cancer cachectic patients, such as lipid‐
mobilizing factor, as well as about the derangement in the neuroendocrine regulation of food 
intake and anorexia [60]. Additionally, changes in carbohydrate, lipid, and protein metabo‐
lism account for altered substrate metabolism. Changes in resting energy expenditure (REE) 
are considered one of the causes of nutritional depletion in cancer. In particular, measured 
REE by indirect calorimetry (IC) was elevated in patients with newly detected esophageal 
Figure 1. Example of CT scan analysis by the Slice‐O‐Matic software. Lumbar vertebrae 3 slice with Hounsfield units 
used to measure area of skeletal muscle, subcutaneous fat and visceral fat. White outer ring, subcutaneous fat; Light grey 
inner ring, muscle; Dark grey central area, visceral fat. Reproduced from Gibson et al. [42].
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cancer, compared to healthy individuals [61]. A cross‐sectional study involved 30 patients 
admitted with a diagnosis of squamous cell carcinoma who underwent IC before starting 
cancer therapy. The basal energy expenditure (BEE) was evaluated using IC and was also 
estimated using the Harris‐Benedict Equation (HBE). The results showed that BEE of patients 
with squamous cell carcinoma was underestimated when using the HBE [62]. However, cur‐
rent evidence is inconsistent, since some studies suggest that REE is normal and is not affected 
by stage of disease [63–65]. Consequently, more research should be conducted in order to 
shed light on this controversial field.
3. Perioperative nutritional care
3.1. Enteral versus parenteral nutrition
Esophagectomy is one of the most invasive and time‐consuming operations among gastro‐
intestinal surgical procedures. It induces a strong stress response in the human body [66]. 
Consequently, patients’ nutritional status is deteriorated after surgery, making postoperative 
nutritional care very important. The use of enteral nutrition (EN) postoperatively is a matter 
of debate, while scientific research attempts to define the role of enteral and parenteral nutri‐
tion (PN) on the clinical outcome of patients undergoing esophagectomy. Enteral feeding is 
considered the method of choice for the nutritional support of cancer patients with function‐
ing gastrointestinal tract. Enteral nutrition is advantageous over parenteral nutrition for the 
following reasons: it provides all the necessary micro‐ and macronutrients in a more intact 
form, maintains gut mucosal integrity, inhibits the cytokine response, reduces the secretion 
of stress hormones, inhibits bacterial translocation, has a decreased risk of complications, and 
is less expensive [67]. Nevertheless, enteral nutrition is often avoided in order to minimize 
strain to the anastomoses, and reduce the risk of postoperatively impaired gastrointestinal 
motility. Another concern involves the return of gut motility or peristalsis and the ability of 
the gut to absorb nutrients. Surgical advances have increased the integrity of all anastomoses, 
making early oral enteral feeding after surgery a feasible option.
A randomized control trial investigated the outcomes of PN or EN after thoracoscopic esoph‐
agectomy. The rate of weight loss at postoperative day (POD) 14 was significantly lower in the 
EN group than in the PN group. Prealbumin levels at POD 10 showed no differences between 
the two groups. However, the incidence of postoperative pneumonia was higher in the PN 
group than in the EN group [68]. The results of another randomized clinical trial showed 
that there was no significant difference between EN and PN groups in terms of postoperative 
serum albumin, prealbumin, or transferrin. However, complement component 3 (C3) and 
4 (C4) levels were significantly higher in the EN group compared with the PN group, while 
C‐reactive protein level was significantly lower in the enteral feeding group. Bowel move‐
ments were restored sooner and costs of treatment were lower in the EN group. Postoperative 
complications did not differ significantly between the two groups [69]. Results from a recent 
meta‐analysis of 10 randomized controlled trials concerning cancer patients following esoph‐
agectomy indicated that early postoperative enteral nutrition could significantly decrease 
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pulmonary complications and anastomotic leakage compared with parenteral nutrition. On 
the eighth postoperative day, the EN group had higher levels of albumin and prealbumin 
compared with the PN group, suggesting that postoperative EN support is more effective 
in maintaining patients’ nutritional status than PN support. No difference was observed in 
digestive complications between these two approaches. However, this meta‐analysis is char‐
acterized by heterogeneity issues, especially regarding the postoperative nutritional status 
[70]. Furthermore, others suggest that combination of enteral and parenteral feeding is more 
beneficial, since total parenteral nutrition (TPN) could lead to hyperglycemia in stressed 
patients. A combination of EN and TPN might have some benefits when compared to TPN 
alone, such as improvement of intestinal integrity and stimulation of incretin production con‐
tributing to improved glucose control in patients undergoing esophagectomy [71]. Moreover, 
supplemental parenteral nutrition after esophagectomy contributes to better coverage of 
patients’ calorie requirements, since large amounts of enteral nutrition are not usually toler‐
ated in the first postoperative days [72].
The European Society for Parenteral and Enteral Nutrition (ESPEN) guidelines for nutritional 
support recommend that interruption of nutritional intake is unnecessary after surgery in 
most patients and in patients who require postoperative artificial nutrition, enteral feeding, 
or a combination of enteral and supplementary parenteral feeding is the first choice. Also 
this combination should be considered in patients in whom more than 60% of energy needs 
cannot be met via the enteral route. Postoperative parenteral nutrition is beneficial in under‐
nourished patients in whom enteral nutrition is not feasible or not tolerated. In addition, 
postoperative parenteral nutrition is beneficial in patients with postoperative complications 
impairing gastrointestinal function that are unable to receive and absorb adequate amounts of 
oral/enteral feeding for at least 7 days [28]. Moreover, the American Society for Parenteral and 
Enteral Nutrition (ASPEN) guidelines for critically ill patients recommends that patients who 
have undergone major upper gastrointestinal tract surgery and EN is not feasible, PN should 
be initiated (only if the duration of therapy is anticipated to be more than 7 days). Unless 
the patient is at high nutrition risk, PN should not be started in the immediate postoperative 
period, but should be delayed for 5–7 days [73]. In conclusion, although enteral nutrition 
seems to be a safe and feasible option postoperatively in terms of immunological parameters 
and postoperative complications, no firm conclusion can be drawn regarding postoperative 
nutritional markers that reflect patients’ nutritional status.
3.2. Time of feeding
3.2.1. Early enteral nutrition
The initiation of enteral feeding after esophagectomy remains a controversial topic and many 
studies examine whether or not early enteral feeding affects negatively or positively the post‐
operative outcome. One study that investigated early enteral feeding after esophagectomy 
included 208 patients who received enteral nutrition postoperatively and were divided into 
three groups (Group 1, 2, and 3) based on whether they received EN within 48 h, 48–72 h 
or more than 72 h, respectively. The postoperative complications, length of hospital (LOH) 
stay, days for first fecal passage, cost of hospitalization, and the difference in serum albumin 
values pre‐ and postoperatively were all recorded. Group 1 had the lowest thoracic drainage 
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volume, the earliest first fecal passage, and the lowest LOH and hospitalization expenses of 
all the three groups. The incidence of pneumonia was higher in Group 3. Finally, all postop‐
erative outcomes of nutritional status were worst in Group 3 [74]. Similarly, one systematic 
review demonstrated that early oral EN was associated with reduced length of stay and did 
not increase complication rates [75]. More randomized clinical trials are required to confirm 
the results from retrospective studies that indicated that early EN promotes early recovery of 
intestinal movement and better recovery from systemic inflammation [66]. In addition, current 
literature is inconclusive with respect to the right time of EN administration postoperatively, 
that is, EN initiation within 24 h versus EN initiation during 24–72 h [76, 77].
3.2.2. Enhanced recovery after surgery (ERAS)
Early enteral nutrition is an essential part of fast‐track surgery protocols in order to maximize 
the effects of enhanced recovery. Fast‐track programs incorporate new methods regarding anes‐
thesia, nutritional care, pain control, and surgical techniques in the preoperative, intraopera‐
tive, and postoperative period, aiming to promote postoperative rehabilitation of patients [78]. 
ESPEN guidelines recommend that all cancer patients undergoing either curative or palliative 
surgery should be managed within an enhanced recovery program postoperatively; within this 
program every patient should be screened for malnutrition and if deemed at risk, given addi‐
tional nutritional support [79]. Nutritional aspects of ERAS could be summarized as follows: 
limitation of preoperative fasting, preoperative fluid and carbohydrate loading, and initiation 
of oral diet on the first postoperative day [80]. A recently published review demonstrated that 
utilization of enhanced recovery programs in esophageal cancer patients was associated with a 
reduction in the incidence of anastomotic leak, pulmonary complications, and length of hospi‐
tal stay, but no significant change was observed in postoperative mortality or readmission rate. 
Nevertheless, there was significant heterogeneity between the studies in terms of enhanced 
recovery protocols, surgical approach, and utilization of neoadjuvant therapies that should be 
taken into account [81]. Results from a randomized controlled clinical study showed that the 
implementation of a fast‐track protocol improved postoperative clinical recovery and cellular 
and humoral immunity of patients undergoing esophagectomy for esophageal cancer (Table 2) 
[82]. In this context, the implementation of fast‐track programs in esophagectomy patients is 
promising, but the majority of patients included in the studies are relatively healthy patients. 
More randomized controlled studies and evidence‐based research are required in order to jus‐
tify the routine use of fast‐track protocols in esophageal cancer patients [83].
3.3. Perioperative immunonutrition
Immunonutrition is one of the most debated topics in nutritional support of esophageal can‐
cer patients. The term immunonutrition includes formulas that contain immune‐modulating 
substances, such as arginine, glutamine, ribose nucleic acid, and omega‐3‐fatty acids. A recent 
review concluded that postoperative enteral immunonutrition could be promising in improv‐
ing humoral immunity in patients undergoing esophagogastric resection, but this improvement 
is not related to a reduced hospital stay, nor does it reduce the rate of infections. The authors 
reported that there is heterogeneity regarding the types of operations undertaken (two studies 
included patients undergoing esophagectomy, three studied patients undergoing gastrectomy, 




POD1 Jejunostomy tube feeding 500 ml (starting at 20 ml/h)
Early postoperative mobilization program
(>2 h out of bed)
Physical therapy and nebulizers
Remove urine catheter
Head of bed put at 30°
Supply albumin
Chest tube to suction
Promoted to lung recruitment
POD2 Jejunostomy tube feeding 1000 ml (40 ml/h)
Chest tube to suction
Expand mobilization (>4 h out of bed)
Continue physical therapy and nebulizers
Continue supply albumin
POD3 Jejunostomy tube feeding 1500 ml (60–80 ml/h)
Remove chest tube
Remove epidural catheter
Expand mobilization (>6 h out of bed)
Continue physical therapy and nebulizers
Continue supply albumin
POD4 Gastrograffin opacification of upper gastrointestine
If swallow shows no leak, advance patient to oral drink
Jejunostomy tube feeding 1500 ml (60–80 ml/h)
Continue physical therapy and nebulizers
Education on aspiration precaution
Education on chewing and swallowing
POD5 Jejunostomy tube feeding 1500 ml (60–80 ml/h)
Advance patient to a full liquid diet
Continue aspiration precautions
Continue physical therapy and nebulizers
POD6 Increase liquid diet
Decrease jejunostomy tube feeding
(500 or 1000 ml)
Continue aspiration precautions
Continue physical therapy and nebulizers
POD7 Remove jejunostomy tube
Full liquid diet
Discharge home on soft diet and liquid diet
Continue aspiration precautions
Note: FTS: Fast track surgery. Adapted from Chen et al. [82].
Table 2. Daily guideline of postoperative care of patients with fast‐track surgery pathway.
Esophageal Abnormalities98
and one had patients undergoing both operations). Additionally, the included randomized 
clinical trials used different formulations of enteral immunonutrition and standard enteral 
nutrition, further limiting the accuracy of the results. Moreover, not all studies reported the 
same outcomes as far as inflammatory and immunological markers are concerned. Therefore, 
the authors suggest that there is no convincing evidence in terms of routine immunonutrition 
in patients undergoing esophageal resection for cancer [84].
On the other hand, preoperative nutritional supplementation with immune‐enhancing for‐
mulas was associated with reduced infectious complications, duration of hospitalization, 
improved short‐term survival and less mortality in patients with esophageal cancer. These 
results highlight the possible need to provide immunonutrients before surgery to obtain suf‐
ficient levels at the time of surgical stress when there is an increased need for stimulation of 
the immune system [85]. One meta‐analysis that included studies with patients that under‐
went esophagectomy, gastrectomy and pancreatectomy, demonstrated that patients who 
received immunonutrition postoperatively, had a significantly lower risk of wound infec‐
tion and shorter length of hospital stay. No significant effect of immunonutrition on other 
postoperative morbidities and mortality was noticed [86]. The reduction in hospital stay and/
or in postoperative complications seems to compensate for the higher cost of immunonutri‐
tion compared to standard enteral feeding in a cost‐effectiveness analysis [87]. According to 
ESPEN guidelines on nutrition in cancer patients, upper gastrointestinal tract cancer patients 
undergoing surgical resection should receive oral/enteral immunonutrition in the context of 
traditional perioperative care [79]. Furthermore, ASPEN guidelines suggest the routine use of 
an immunemodulating formula (containing both arginine and fish oils) in the surgical inten‐
sive care unit for the postoperative patient who requires enteral nutrition therapy [73].
Synbiotics, which are a combination of prebiotics and probiotics, are speculated to have 
beneficial effects on human health, but little is known about their clinical value in patients 
who have undergone esophagectomy. Administration of synbiotics prevented postoperative 
deterioration of the intestinal microfloral environment and suppressed excessive inflamma‐
tory response, possibly by exerting immunomodulatory effects and by inhibiting bacterial 
translocation [88, 89]. Additionally, synbiotics led to decreased incidence of severe diarrhea 
and lower interruption or reduction of enteral nutrition. Passage of flatus postoperatively 
occurred significantly earlier in patients who received synbiotics than in the control group, 
suggesting that synbiotics maintain intestinal motility [88]. Taking all the aforementioned 
things into consideration, larger scale studies are needed in order to define whether or not 
immunonutrition has beneficial effects on the postoperative outcome of esophageal cancer 
patients. Future research should focus on the optimal dose of specific immunonutrients, on 
the timing (preoperatively and/or postoperatively) and duration of immunonutrition delivery 
and clarify which is the target group the intervention should be addressed to.
3.4. Type of feeding
Enteral feeding postoperatively seems to be the method of choice for uncomplicated esopha‐
geal cancer patients. Enteral feeding options after surgery include mainly nasoenteric tubes 
and jejunostomy catheters, in order to bypass recently constructed anastomoses. However 
there is no general agreement regarding the best method for postoperative feeding, and the 
Nutritional Management of Esophageal Cancer Patients
http://dx.doi.org/10.5772/intechopen.69607
99
optimal access route remains questionable. Tube‐related complications include occlusion, 
catheter displacement and local cellulitis at the site of insertion. More severe complications 
include leakage into the peritoneal cavity resulting in peritonitis, volvulus at the point of 
fixation to the anterior abdominal wall, aspiration pneumonia, necrotizing fasciitis or jejunal 
necrosis at the site of catheter insertion and septicemia [90, 91].
A retrospective analysis of 90 patients who underwent esophagectomy demonstrated that 
early enteral nutrition can be administered using three different routes (nasojejunal tube, 
jejunostomy tube, and pharyngostomy tube) with similar results regarding tube‐related 
complications, length of stay, and 30‐day morbidity [92]. Another study of esophageal can‐
cer patients with dysphagia examined the effects of jejunostomy feeding on weight loss and 
treatment outcomes. The palliative group of patients was able to maintain a stable weight 
despite the presence of cancer cachexia. This was also evident in the esophagectomy group 
of patients despite the catabolic effect of the operation, indicating the effectiveness of the jeju‐
nostomy feeding catheter as a means of nutritional support. The feeding catheter was well 
tolerated by the majority of patients (86.8%) and the most frequently occurred complications 
included catheter clogging (10.1% of the study population) and catheter dislodgement (3.1% 
of the study population) [93]. A randomized clinical study that compared nasoenteric tubes 
to jejunostomy feeding in upper gastrointestinal tract cancer patients showed that the length 
of enteral feeding use was less in the nasoenteric group and parenteral feeding was required 
more frequently than in jejunostomy feeding group. Complications related to the different 
feeding routes were similar between the two groups [94]. A recent review investigated the 
best route for enteral nutrition following esophagectomy (oral intake, jejunostomy, or naso‐
jejunal tube feeding) in terms of postoperative complication rates, percentage of patients 
meeting their nutritional needs, weight loss, tube feeding complications, mortality, patient 
satisfaction, and length of hospital stay. Complications and catheter efficacy did not differ 
between postoperative nasojejunal tube feeding and jejunostomy tube feeding. Moreover, 
jejunostomy feeding patients were able to meet their short‐term nutritional requirements, 
but data concerning long‐term outcomes and patients satisfaction were scarce. This review 
concluded that the best route for the delivery of early enteral nutrition postoperatively is 
still unclear [75].
ESPEN guidelines on enteral nutrition in surgical patients recommends that tube feed‐
ing should be applied in patients who cannot start early oral nutrition, including those 
undergoing gastrointestinal surgery for cancer and patients with obvious undernutrition 
at the time of surgery, in whom oral intake will be inadequate (<60%) for more than 10 
days. Initiation of tube feeding should start within 24 h after surgery with a low flow rate 
(i.e. 10–20 ml/h) due to limited intestinal tolerance. Placement of a needle catheter jejunos‐
tomy or nasojejunal tube is recommended for all candidates for tube feeding undergoing 
major abdominal surgery. When anastomoses of the proximal gastrointestinal tract have 
been performed, enteral nutrition should be delivered via a tube placed distally to the 
anastomosis [95].
Postoperative nutritional management of esophageal cancer patients can be summarized as 
in Figure 2.
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4. Nutritional care during chemoradiotherapy
4.1. Nutrition issues during chemotherapy and radiotherapy
Currently, perioperative chemotherapy is frequently administered for the treatment of 
resectable advanced esophageal cancer. The neoadjuvant administration of chemother‐
apy or chemoradiotherapy preoperatively results in reduced tumor size before surgery. 
Perioperative chemotherapy improves significantly disease‐free survival and overall survival 
rates compared to surgery alone. However, a great percentage of these patients are not able 
to complete the planned postoperative chemotherapeutic regimens. This is mainly caused 
because of postoperative complications and impaired nutritional and physical status [96–98]. 
Gastrointestinal disorders caused by chemotherapy itself, including nausea, vomiting, diar‐
rhea, and anorexia, negatively affect patients’ quality of life and make completion of chemo‐
therapy difficult. Neoadjuvant chemotherapy induces changes in body composition which, 
in turn have negative impact on clinical outcomes. Results from a small cohort of esophageal 
cancer patients showed that 26% of patients were sarcopenic before the initiation of neoad‐
juvant chemotherapy and this percentage increased to 43% after its completion. There was 
Figure 2. Postoperative nutritional management of esophageal cancer patients.
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a significant loss of fat mass and skeletal muscle mass which was associated with risk of 
circumferential resection margin positivity [50]. In another study, sarcopenia was present in 
56 and 67% of patients before and after neoadjuvant chemoradiotherapy, respectively. This 
decrease in muscle mass was predictive of postoperative mortality in the stage III–IV sub‐
group of patients [99]. Furthermore, most of the radiotherapy‐related toxicities are strongly 
associated with patient’s nutritional status. Esophagitis is the main toxicity during radio‐
therapy in esophageal cancer patients. These patients often suffer from pain and difficulties 
in swallowing [100]. One study in patients receiving concurrent chemoradiotherapy revealed 
that malnutrition was observed in 83.8% of patients, while 68.8% of patients developed severe 
dysphagia. Malnourished patients developed more treatment‐related toxicities compared to 
those without malnutrition. Patients with impaired nutritional status presented severe dys‐
phagia, anorexia, severe nausea/vomiting, and severe hematologic toxicities more frequently 
than those in a good nutrition status [17]. Although nutritionally related side effects occur fre‐
quently, nutritional assessment of patients with cancer receiving chemoradiotherapy is often 
omitted in the clinical setting. Scientific research has to focus on nutritional interventions 
during neoadjuvant chemoradiotherapy or postoperative adjuvant therapy that seems to 
improve patients’ nutritional status, alleviate symptoms and increase tolerance to therapies.
4.2. Nutritional interventions during chemoradiotherapy
The type and timing of nutritional interventions during chemoradiotherapy challenge the 
caregivers, since a multidisciplinary approach seems more effective in managing treatment’s 
side effects. Current literature emphasizes mainly on the immunomodulatory effects of some 
nutrients, on the impact of oral/tube administration of high‐energy, and/or high protein sup‐
plements on the clinical outcome and on patients education about selecting an enriched diet. 
In cancer patients, it has been shown that the use of supplemental formulas and n‐3 fatty 
acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can improve 
body composition, preserve muscle mass, and possibly reverse or stop the development 
of cancer cachexia [101]. A controlled, randomized prospective, double‐blind, multicenter 
study investigated the impact of enteral nutrition (via percutaneous endoscopic gastrostomy 
(PEG)) enriched with EPA and DHA on body composition, nutritional and functional status 
of esophageal and head and neck cancer patients undergoing concurrent chemoradiotherapy. 
There was a tendency toward improvement regarding loss of body cell mass and body weight 
following chemoradiotherapy, but did not reach statistical significance. However, Karnofsky 
score and subjective parameters, such as the NRS 2002 and the SGA score were significantly 
improved in the experimental group compared with the control group, indicating improved 
nutritional and functional status [102]. Similar results reported by another randomized dou‐
ble‐blind clinical trial showed that administration of immunonutrition during chemoradio‐
therapy in head and neck and esophageal cancer patients was advantageous over standard 
enteral nutrition in terms of body weight, lean body mass, serum albumin levels, NRI assess‐
ment, plasma antioxidant capacity, and functional capacity [103].
Moreover, immunonutrition can modulate the immunological and inflammatory systems, 
thus reducing the risks of concurrent chemoradiotherapy. One randomized clinical trial 
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examined the effects of immunonutrition on serum cytokine and inflammatory markers, and 
cellular immunity in locally advanced esophageal cancer patients undergoing chemoradio‐
therapy. The levels of C‐Reactive Protein (CRP) and TNF increased more during treatment in 
the control group (standard enteral nutrition) than in the treatment group, whereas all other 
markers did not differ significantly between the two groups [104]. In addition, the impact 
of immunonutrients on immune system of head and neck and esophageal cancer patients 
during chemoradiotherapy was examined in another randomized clinical trial. Immune cells 
metabolism and functions were assessed at the initiation and at the completion of treatment. 
The experimental group had better adaptation to the systematic inflammation and oxida‐
tive stress, as indicated by CD4+/CD8+ T‐lymphocyte counts ratio, CD3 membrane expression, 
polymorphonuclear cells CD62L and CD15 densities, reactive oxygen species (ROS) produc‐
tion, and peripheral blood mononuclear cells production of pro‐inflammatory prostaglandin‐
E2 [105].
Another role of immunonutrition is the potential protection against chemotherapy‐induced 
toxicities. Miyata et al. compared the effects between enteral nutrition rich in n‐3 fatty acids 
(900 mg/d) and enteral nutrition poor in n‐3 fatty acids (250 mg/d) on chemotherapy‐related 
adverse events and inflammatory markers during neoadjuvant chemotherapy in esoph‐
ageal cancer patients. This randomized control trial showed no significant difference in 
the incidence of grade 3/4 leukopenia and neutropenia, but stomatitis was observed less 
frequently in the n‐3‐rich group, than in the n‐3‐poor group. Grade 3/4 diarrhea was also 
observed less frequently in the n‐3‐rich group than in the n‐3‐poor group, but this was not 
statistically significant. Moreover, n‐3‐rich enteral nutrition seems to have hepatoprotec‐
tive properties by preventing an increase of aspartate aminotransferase and alanine amino‐
transferase values [106].
Synbiotics seem also to mitigate chemotherapy‐related side effects through adjustments to 
the intestinal microbiota. A randomized clinical trial investigated the effects of synbiotics in 
esophageal cancer patients undergoing neoadjuvant chemotherapy, on the intestinal microbi‐
ota, and the adverse events of treatment. Severe lymphopenia and diarrhea were less frequent 
in patients who received synbiotics than in the control group. Furthermore, febrile neutrope‐
nia occurred less in the synbiotics group compared to the control group [107]. Chemotherapy 
may disturb the intestinal microbiota, leading to reduced production of organic acids in 
the bowel, impaired mucosal integrity, and increased harmful bacteria. These, in turn, may 
induce chemotherapy‐related toxicities, such as diarrhea and infectious complications [108]. 
Administration of synbiotics results in increased concentrations of short‐chain fatty acids, 
such as acetate and propionate. These fatty acids are an important energy source of entero‐
cytes, maintain intestinal environment acidity and intestinal motility. Synbiotics also maintain 
the number of beneficial bacteria and inhibit the overgrowth of possible diarrheal pathogens, 
thus reducing the incidence of diarrhea [109].
ESPEN guidelines on nutrition in cancer patients recommend the supplementation with long‐
chain n‐3 fatty acids or fish oil to stabilize or improve appetite, food intake, lean body mass, 
and body weight in patients with advanced cancer undergoing chemotherapy and at risk 
of weight loss or malnourished [79]. It is therefore evident that immunonutrition enhances 
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immune system and exerts anti‐inflammatory properties, but the promising effects on clini‐
cal outcome during chemoradiotherapy in esophageal cancer are still under investigation. 
Additional clinical trials are needed to determine the preferred type, timing and duration of 
immunonutrition required to reduce inflammation and chemotherapy‐induced toxicities, and 
maintain muscle mass.
Nutritional interventions, other than that examining the impact of specific immunonutrients 
on chemoradiotherapy‐related outcomes, include nutritional counseling and/or enteral sup‐
plements in order to maintain stable body weight and cope with feeding difficulties (Table 3). 
A recent randomized controlled trial compared the effects of a walk‐and‐eat intervention 
versus conventional medical care for patients with esophageal cancer undergoing neoadju‐
vant chemoradiotherapy. This intervention consisted of a structured walking protocol and 
weekly nutritional advice including weight and intake evaluation, counseling to overcome 
feeding difficulties, supplementation, if necessary, with enteral formulas, and patient’s edu‐
cation concerning food texture modification and oral care before and after eating. During 
chemoradiotherapy, the group that received the walk‐and‐eat intervention had 100‐m less 
decline than controls in walk distance, 3 kg less decrease in handgrip strength, and 2.7 kg 
less reduction in body weight. Moreover, the experimental group had significantly reduced 
rates of intravenous nutritional support and wheel chair use [110]. Another randomized trial 
tested the effects of an interdisciplinary nutrition support team on clinical and hospitalized 
outcomes of esophageal cancer patients receiving concurrent chemoradiotherapy. Nutritional 
support included dietary counseling, oral nutritional supplements, enteral nutrition, and 
parenteral nutrition according to patient’s needs. At the completion of treatment, nutritional 
status of patients in the interventional group was better compared to control group, as dem‐
onstrated by prealbumin, transferrin, and albumin levels. Bone marrow suppression and 
complications related to infections were significantly lower in the nutritional support group. 
Nutritional intervention was also associated with a lower average length of hospital stay and 
in‐patient cost [111]. Furthermore, nutritional intervention improved survival of esophageal 
cancer patients treated with definitive chemoradiotherapy. It is noticeable that this effect was 
observed only if nutritional support was provided at baseline (dietary advice, oral supple‐
mentation, or major intervention), and not if provided later in the treatment course [10].
According to ESPEN, in patients receiving radiotherapy, especially radiotherapy of the head 
and neck, thorax, and gastrointestinal tract, an adequate nutritional intake should be ensured 






Table 3. Nutritional interventions during chemoradiotherapy.
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 supplements, in order to avoid nutritional deterioration, maintain intake, and avoid radio‐
therapy interruptions. In addition, for patients undergoing curative anticancer drug treat‐
ment who cannot meet their nutritional requirements despite counseling and oral nutritional 
supplements, ESPEN recommends supplemental enteral nutrition or, if this is not sufficient 
or possible, parenteral nutrition [79]. Therefore, assessment and maintenance of good nutri‐
tional status at baseline may be a simple and cost‐effective intervention that improves clinical 
outcomes in esophageal cancer patients during chemoradiotherapy treatment.
4.3. Stent insertion
There are various types of stents available, such as self‐expandable metallic stents, self‐
expandable plastic stents, and biodegradable stents. Esophageal stenting can be implemented 
to relieve dysphagia during preoperative chemotherapy and/or radiotherapy. A systematic 
review investigated the impact of stent insertion during neoadjuvant treatment on dysphagia 
improvement. Placement of an esophageal stent significantly improved overall dysphagia 
scores in all 12 studies reviewed. However, no consistent improvement in nutritional status 
was observed, defined by body weight and albumin levels. Moreover, stent insertion was 
associated with complications, such as migration and chest pain, frequently resulting in stent 
removal or replacement [112]. The European Society of Gastrointestinal Endoscopy (ESGE) 
does not recommend self‐expandable metal stents placement as a bridge to surgery or prior 
to preoperative chemoradiotherapy, since it is associated with a high incidence of adverse 
events. Other options, such as feeding tube placement are preferable and should be consid‐
ered in dysphagic or malnourished patients in the neoadjuvant setting [113].
5. Palliative care
Management of patients undergoing noncurative treatments due to advanced disease is dif‐
ficult, since the goals are not to cure patients but to improve length and quality of remaining 
life. Nutritional support is a crucial part in the palliative care as long as its benefits outweigh 
its costs. Patients with metastatic disease present for the clinician not only clinical but ethical 
issues as well. Dysphagia is the main symptom in patients with unresectable disease which 
aggravates malnutrition and requires nutritional intervention [114]. Nutritional support of 
these patients includes intravenous fluids for hydration, feeding tubes, parenteral nutrition, 
and stent placement in order to supplement dietary and caloric intake. Various techniques 
have been proposed to manage dysphagia, such as brachytherapy, self‐expanding metal 
stents, thermal laser therapy, and photodynamic therapy. Each one of them has specific advan‐
tages and risks that should be taken into consideration. The authors of a recent meta‐analysis 
of 53 randomized controlled trials concluded that self‐expanding metal stent insertion is safe, 
effective, and improves dysphagia faster compared to other modalities. High‐dose intralumi‐
nal brachytherapy is a satisfactory alternative and might provide additional survival benefit 
with a better quality of life. Combinations of brachytherapy with self‐expanding metal stent 
insertion or radiotherapy seem to be the preferable option addressed to inoperative patients 
[115]. ESGE recommends placement of partially or fully covered self‐expandable metal stents 
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for palliative treatment of malignant dysphagia over laser therapy, photodynamic therapy, 
and esophageal bypass [113].
Moreover, in esophageal cancer patients with short life expectancy unsuitable for esopha‐
geal stenting, percutaneous endoscopic gastrostomy (PEG) may be a suitable means in order 
to achieve nutritional support, while allowing patients to be at home [116]. Endoscopically 
assisted nasogastric tube feeding is also a feasible palliative option for nutritional support, 
with a low complication rate. Tube‐feeding patients had significantly higher enteral calorie 
intake, higher serum albumin, shorter hospital stay, and longer median survival compared 
to those who received nil per os, according to a retrospective study of patients with malig‐
nant esophageal obstruction [117]. Palliative care in the terminal phase should be followed 
in an individualized manner. ESPEN recommends that in dying patients, artificial hydra‐
tion and nutrition are unlikely to benefit patients. Nevertheless, in acute confusional states, 
patients might receive a short and limited hydration to rule out dehydration as precipitat‐
ing cause [79].
6. Conclusion
Esophageal cancer patients suffer from malnutrition and cannot easily meet their nutritional 
needs. Nutritional assessment, in the perioperative phase, but also in patients undergoing 
chemoradiotherapy should be performed regularly, in order to identify undernourished 
patients. Regarding the perioperative management of these patients, early enteral nutrition 
support seems to be the method of choice in uncomplicated patients, especially as a part of 
ERAS programs. However, the impact of immunonutrition on clinical outcome is still under 
investigation. During chemoradiotherapy, prevention of weight loss is of great significance 
and might be achieved through close nutritional monitoring. Nutritional support mainly 
encompasses dietary counseling, oral supplementation, tube feeding, and combination of 
them and has promising results in ameliorating nutritional status and affecting the oncologic 
outcome. Moreover, patients with terminal‐stage esophageal cancer might benefit from early 
stent insertion in order to reduce dysphagia. Individualized nutritional support should be 
addressed to every patient who is in need of nutritional intervention.
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